microplasmin

consists or two polypeptide chains connected by disulfide bonds; one chain is the B chain of plasmin consisting of 230 amino acids, the other peptide is the COOH-terminal portion of the A chain of plasmin consisting of 31 amino acid residues; MW 28.635kDa

Also Known As:

Networked: 179 relevant articles (28 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Haller, Julia A: 9 articles (01/2020 - 04/2010)
2.	Jackson, Timothy L: 8 articles (05/2022 - 01/2016)
3.	Girach, Aniz: 8 articles (03/2016 - 08/2012)
4.	Stalmans, Peter: 7 articles (02/2021 - 07/2009)
5.	Kampik, Anselm: 7 articles (10/2015 - 02/2004)
6.	Lescrauwaet, Benedicte: 6 articles (05/2022 - 01/2016)
7.	Dugel, Pravin U: 6 articles (07/2020 - 07/2015)
8.	Jaffe, Glenn J: 6 articles (01/2019 - 09/2012)
9.	Toth, Cynthia A: 6 articles (01/2019 - 09/2012)
10.	Pakola, Steve: 6 articles (10/2012 - 09/2002)

Related Diseases

1.	Retinal Perforations 07/01/2016 - "Patients should be informed about the potential adverse events of ocriplasmin, although they mainly seemed to be transient and usually mild/moderate in severity, suggesting that ocriplasmin is a safe and effective new treatment alternative for VMT and macular hole. " 01/01/2021 - "To assess the effect of patient baseline characteristics on the efficacy of ocriplasmin treatment for symptomatic vitreomacular adhesion (VMA) with full-thickness macular hole (FTMH) from phase 3/4 studies. " 01/01/2021 - "Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies." 01/01/2020 - "Efficacy of ocriplasmin was derived from logistic regression models using Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole trial data. " 12/01/2018 - "The purpose of this study is to provide an updated assessment of cost-efficacy of intravitreal ocriplasmin (IVO) for vitreomacular adhesion (VMA) and macular holes (MH). "
2.	Epiretinal Membrane (Epiretinal Membranes) 06/01/2016 - "The two best studies concluded that ocriplasmin is cost-effective in their respective countries (Canada and United Kingdom), but only in patients with certain conditions (without epiretinal membrane, for example). " 01/01/2016 - "Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane. " 07/01/2015 - "Ocriplasmin demonstrated efficacy in closure of small and medium FTMH, and in FTMH without epiretinal membrane at baseline. " 12/01/2016 - "Subgroup analysis of these clinical trials as well as post-marketing clinical series have aided in patient selection by identifying features associated with successful pharmacologic release of VMT with ocriplasmin, including adhesion diameter ≤1500 μm, absence of epiretinal membrane, phakic status, and age younger than 65. " 03/01/2015 - "The study is a retrospective chart review of patients who would have high chances of a benefit by an Ocriplasmin injection, without epiretinal membrane or vitreomacular adhesion of 1500 µm or more on SD-OCT. "
3.	Vitreous Detachment (Posterior Vitreous Detachment) 11/01/2021 - "Ocriplasmin has been developed for the induction of posterior vitreous detachment in patients with vitreomacular adhesion. " 01/01/2018 - "Intravitreal ocriplasmin injection induced resolution of VMT in most cases and more rarely a release of vitreopapillary adhesion and a complete posterior vitreous detachment. " 08/16/2012 - "Total posterior vitreous detachment was more prevalent among the eyes treated with ocriplasmin than among those injected with placebo (13.4% vs. 3.7%, P<0.001). " 02/01/2011 - "Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. " 10/01/2010 - "Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment."
4.	Macular Degeneration (Age-Related Maculopathy) 04/01/2015 - "Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration." 04/01/2015 - "The evaluation of the safety and preliminary efficacy of 125 μg ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD). " 04/01/2015 - "Thus, long-term studies are needed to define a role for pharmacologic vitreolysis, in particular with ocriplasmin, in the prevention of progressive diabetic retinopathy and age-related macular degeneration." 07/01/2009 - "To evaluate the safety and preliminary efficacy of 4 doses and several exposure times of intravitreal microplasmin given before pars plana vitrectomy for vitreomacular traction maculopathy. " 03/01/2016 - "Using this algorithm, we describe the findings in multiple clinical examples, including normal controls, age-related macular degeneration, drug effects (eg, ocriplasmin, hydroxychloroquine) and effects of surgical manipulation (eg, following membrane peeling using intraoperative OCT). "
5.	Thrombosis (Thrombus) 06/01/2012 - "The primary outcome was complete thrombolysis defined as >95% thrombus volume reduction at the end of the microplasmin infusion. " 04/01/2011 - "A novel human microplasmin fold: new perspective to thrombosis treatment." 11/01/2009 - "We investigated the safety and efficacy of intra-catheter microplasmin bolus administration for the restoration of catheter function in long-term venous access catheter thrombosis. " 11/01/2009 - "A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis." 02/01/2003 - "The effect of recombinant human microplasmin was studied in ischemic stroke models in mice and in an extracorporeal loop thrombosis model in rabbits. "

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	salicylhydroxamic acid (SHAM)
3.	perflutren (octafluoropropane)
4.	Copper
5.	microplasmin
6.	Fibrinolysin
7.	Enzymes
8.	Platinum
9.	Hyaluronoglucosaminidase (Hyaluronidase)
10.	Retinaldehyde (Retinal)

Related Therapies and Procedures

1.	Traction
2.	Intravitreal Injections
3.	Vitrectomy
4.	Catheters
5.	Aftercare (After-Treatment)